γ-tocopheryl acetate | 2831-64-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: γ-tocopheryl acetate
• 英文别名: tocopheryl acetate；(all-rac)-γ-tocopheryl acetate；γ-tocopherol acetate；(+)-gamma-Tocopherol, O-acetyl-；[2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] acetate
• CAS: 2831-64-3；38365-45-6
• 化学式: C₃₀H₅₀O₃
• 分子量: 458.725
• InChiKey: FOYKKGHVWRFIBD-UHFFFAOYSA-N

物化性质

• 沸点：
  530.5±49.0 °C(Predicted)
• 密度：
  0.944±0.06 g/cm3(Predicted)
• 保留指数：
  3118

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  33
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  γ-tocopheryl acetate 在 碘 、 silver trifluoroacetate 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以80%的产率得到[5-Iodo-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] acetate
  参考文献：
  名称：

  Kumadaki, Itsumaro; Hirai, Masami; Koyama, Mayumi, Synthetic Communications, 1989, vol. 19, # 1, 2, p. 173 - 178

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二氢-2,7,8-三甲基-2-(4,8,12-三甲基十三烷)-2H-1-苯并吡喃-6-醇 、 乙酸酐 在 11percent Ca +50 percent Na on SiO₂ prepared from Ca(OH)2 + Na silicate 作用下， 反应 4.25h， 以95%的产率得到γ-tocopheryl acetate
  参考文献：
  名称：

  [EN] PROCESS FOR THE MANUFACTURE OF TOCOPHERYL ACYLATES
  [FR] PROCEDE DE FABRICATION D'ACYLATES DE TOCOPHERYLE

  摘要：

  本发明涉及一种制备生育酚酰酸酯的方法，包括在固体碱性催化剂的存在下，将生育酚与酰化剂反应，所述固体碱性催化剂包括碱金属和/或碱土金属，优选在固体载体上，并且涉及在生育酚的酰化中使用这种催化剂。

  公开号：

  WO2005103026A1

文献信息

• REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
  申请人：Miller Guy M.

  公开号：US20100222436A1

  公开（公告）日：2010-09-02

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明揭示了治疗或抑制线粒体疾病的方法，如弗里德雷希共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或柯恩斯-萨耶综合症（KSS），以及在所述方法中有用的化合物，如α-生育酚醌。本发明还揭示了用于治疗其他疾病的方法和化合物。还揭示了有用于评估受试者代谢状态和治疗效果的能量生物标志物。本发明还揭示了调节、规范或增强能量生物标志物的方法，以及用于此类方法的化合物。
• Cured gel and method of making
  申请人：Atrium Medical Corporation

  公开号：US10016465B2

  公开（公告）日：2018-07-10

  A cured non-polymeric gel including a plurality of non-polymeric cross-links. The non-polymeric cross-links result from curing an oil or oil composition at selected curing conditions to achieve a desired amount of cross-linking to form the non-polymeric get. The desired amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted. The oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alphalinolenic acid (ALA).

  一种固化的非聚合物凝胶，包括多个非聚合物交联。非聚合交联产生于在选定的固化条件下固化油或油组合物，以达到所需的交联量，从而形成非聚合凝胶。所需的交联量是根据凝胶植入后所需的降解率来选择的。油或油组合物包含二十碳五烯酸（EPA）、二十二碳六烯酸（DHA）或α-亚麻酸（ALA）中的一种或多种。
• Infant nutritional product with RRR alpha-tocopherol
  申请人：ABBOTT LABORATORIES

  公开号：US10328049B2

  公开（公告）日：2019-06-25

  This invention relates to a method of improving CNS maturation in an infant by administering a mixture of natural tocopherols, wherein the composition contains an optimum tocopherol profile similar to that found in human breast milk, and can encompass a tocopherol profile from early stage to transitional to mature human breast milk. For ease of administration and maximized efficacy, the optimized mixture of natural tocopherols are typically delivered in an oral dosage form with a limited level of non-RRR alpha-tocopherols to maximize efficacy of the RRR alpha-tocopherol on stimulating post-natal CNS development.

  本发明涉及一种通过施用天然生育酚混合物来改善婴儿中枢神经系统成熟的方法，其中该组合物含有与人类母乳中相似的最佳生育酚谱，可包含从早期母乳到过渡母乳再到成熟母乳的生育酚谱。为了便于给药和发挥最大功效，优化的天然生育酚混合物通常以口服剂型给药，并添加一定量的非 RRR α-生育酚，以最大限度地发挥 RRR α-生育酚对刺激出生后中枢神经系统发育的功效。
• Fatty-acid based particles
  申请人：ATRIUM MEDICAL CORPORATION

  公开号：US10285964B2

  公开（公告）日：2019-05-14

  The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.

  本发明针对的是以脂肪酸为基础的微粒，以及制造这种微粒的方法。这些微粒可与额外的治疗剂结合。本发明还提供了一种形成脂肪酸微粒的方法，包括将交联的脂肪酸衍生生物材料与低温液体结合；以及破碎生物材料/低温液体组合物，从而形成脂肪酸微粒。这种颗粒可用于多种治疗用途。
• Cross-linked fatty acid-based biomaterials
  申请人：ATRIUM MEDICAL CORPORATION

  公开号：US10814043B2

  公开（公告）日：2020-10-27

  Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.

  本文介绍了基于脂肪酸的预固化衍生生物材料、制造这种生物材料的方法以及将其用作药物输送载体的方法。脂肪酸衍生生物材料可单独使用，也可与医疗设备结合使用，用于释放和局部输送一种或多种治疗药物。还提供了形成和调整所述生物材料特性的方法，以及使用所述生物材料治疗哺乳动物损伤的方法。